Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cadonilimab + axitinib (Akeso, Inc.)
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
AK104 + axitinib is an investigational combination therapy comprising cadonilimab (AK104), a bispecific antibody targeting PD-1 and CTLA-4, and axitinib, a small molecule tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3. This combination is designed to provide dual immune checkpoint blockade while simultaneously inhibiting tumor angiogenesis. It is currently being evaluated in Phase Ib clinical trials, specifically for the treatment of metastatic mucosal melanoma, a rare and aggressive subtype of melanoma. Cadonilimab is developed by Akeso, while axitinib is a multi-target TKI originally developed by Pfizer.
- Brand names
- Cadonilimab + Inlyta
- Other names
- AK104 plus axitinibAK-104 plus axitinibAK 104 plus axitinib
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDGFRB (Platelet-derived growth factor receptor beta)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on cadonilimab + axitinib (Akeso, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cadonilimab + axitinib (Akeso, Inc.).